CN114717298A - 一种多重扩增方法 - Google Patents
一种多重扩增方法 Download PDFInfo
- Publication number
- CN114717298A CN114717298A CN202110011778.2A CN202110011778A CN114717298A CN 114717298 A CN114717298 A CN 114717298A CN 202110011778 A CN202110011778 A CN 202110011778A CN 114717298 A CN114717298 A CN 114717298A
- Authority
- CN
- China
- Prior art keywords
- sequence
- amplification
- nucleic acid
- capture oligonucleotide
- universal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003321 amplification Effects 0.000 title claims abstract description 125
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 125
- 238000000034 method Methods 0.000 title claims abstract description 29
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 114
- 238000001514 detection method Methods 0.000 claims abstract description 92
- 239000000047 product Substances 0.000 claims abstract description 56
- 239000013067 intermediate product Substances 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 65
- 150000007523 nucleic acids Chemical class 0.000 claims description 59
- 108020004707 nucleic acids Proteins 0.000 claims description 51
- 102000039446 nucleic acids Human genes 0.000 claims description 51
- 239000000523 sample Substances 0.000 claims description 35
- 230000011987 methylation Effects 0.000 claims description 31
- 238000007069 methylation reaction Methods 0.000 claims description 31
- 230000000295 complement effect Effects 0.000 claims description 30
- 230000000903 blocking effect Effects 0.000 claims description 21
- 108091008146 restriction endonucleases Proteins 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 230000007017 scission Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 125000004149 thio group Chemical group *S* 0.000 claims description 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
- 108060002716 Exonuclease Proteins 0.000 claims description 3
- 101710163270 Nuclease Proteins 0.000 claims description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 102000013165 exonuclease Human genes 0.000 claims description 3
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 claims description 2
- 230000033607 mismatch repair Effects 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 238000003752 polymerase chain reaction Methods 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 2
- 229940035893 uracil Drugs 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 102000004533 Endonucleases Human genes 0.000 claims 2
- 230000008569 process Effects 0.000 abstract description 5
- 239000000543 intermediate Substances 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 62
- 101000632056 Homo sapiens Septin-9 Proteins 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000001976 enzyme digestion Methods 0.000 description 21
- 238000012408 PCR amplification Methods 0.000 description 18
- 238000007403 mPCR Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 108091091807 let-7a stem-loop Proteins 0.000 description 12
- 108091057746 let-7a-4 stem-loop Proteins 0.000 description 12
- 108091028376 let-7a-5 stem-loop Proteins 0.000 description 12
- 108091024393 let-7a-6 stem-loop Proteins 0.000 description 12
- 108091091174 let-7a-7 stem-loop Proteins 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 11
- 230000035772 mutation Effects 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102100028024 Septin-9 Human genes 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 5
- 108050002584 Septin 9 Proteins 0.000 description 5
- 108010006785 Taq Polymerase Proteins 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 239000002679 microRNA Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000012257 pre-denaturation Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 4
- 229960001225 rifampicin Drugs 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000007847 digital PCR Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 2
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101710170648 Actin, alpha cardiac muscle 1 Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 102000010719 DNA-(Apurinic or Apyrimidinic Site) Lyase Human genes 0.000 description 1
- 108010063362 DNA-(Apurinic or Apyrimidinic Site) Lyase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000282696 Saimiri sciureus Species 0.000 description 1
- 108050004875 Septin Proteins 0.000 description 1
- 102000012060 Septin 9 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- -1 meganuclease Proteins 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000009032 regulation of cytokinesis Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150090202 rpoB gene Proteins 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110011778.2A CN114717298A (zh) | 2021-01-06 | 2021-01-06 | 一种多重扩增方法 |
| PCT/CN2022/070427 WO2022148388A1 (zh) | 2021-01-06 | 2022-01-06 | 一种多重扩增方法 |
| DE112022000534.3T DE112022000534T5 (de) | 2021-01-06 | 2022-01-06 | Verfahren zur Multiplex-Amplifizierung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110011778.2A CN114717298A (zh) | 2021-01-06 | 2021-01-06 | 一种多重扩增方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114717298A true CN114717298A (zh) | 2022-07-08 |
Family
ID=82234897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110011778.2A Pending CN114717298A (zh) | 2021-01-06 | 2021-01-06 | 一种多重扩增方法 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN114717298A (de) |
| DE (1) | DE112022000534T5 (de) |
| WO (1) | WO2022148388A1 (de) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882856A (en) | 1995-06-07 | 1999-03-16 | Genzyme Corporation | Universal primer sequence for multiplex DNA amplification |
| US20060216737A1 (en) * | 2005-03-10 | 2006-09-28 | John Bodeau | Methods for multiplex amplification |
| CN104694630B (zh) * | 2015-02-02 | 2017-05-24 | 江苏佰龄全基因生物医学技术有限公司 | 用于多重连接扩增技术的探针制备方法 |
| CN109477105A (zh) * | 2016-05-24 | 2019-03-15 | 阿提拉生物系统股份有限公司 | Ω扩增 |
| CN108300716B (zh) * | 2018-01-05 | 2020-06-30 | 武汉康测科技有限公司 | 接头元件、其应用和基于不对称多重pcr进行靶向测序文库构建的方法 |
| CN108753935A (zh) * | 2018-06-15 | 2018-11-06 | 上海优甲医疗科技有限公司 | 一种降低多重聚合酶链式反应中引物二聚体扩增的方法 |
-
2021
- 2021-01-06 CN CN202110011778.2A patent/CN114717298A/zh active Pending
-
2022
- 2022-01-06 DE DE112022000534.3T patent/DE112022000534T5/de active Pending
- 2022-01-06 WO PCT/CN2022/070427 patent/WO2022148388A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| DE112022000534T5 (de) | 2023-10-26 |
| WO2022148388A1 (zh) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11072819B2 (en) | Methods of constructing small RNA libraries and their use for expression profiling of target RNAs | |
| US8455197B2 (en) | Nucleic acid amplification | |
| CA2863257C (en) | Method for relative quantification of nucleic acid sequence, expression, or copy changes, using combined nuclease, ligation, and polymerase reactions | |
| EP1255871B1 (de) | Amplifizierung mittels multiplex ligationsproben | |
| EP1453979B1 (de) | Multiplex pcr | |
| US20210230670A1 (en) | Solid phase nucleic acid target capture and replication using strand displacing polymerases | |
| EP2615171B1 (de) | Verfahren zur hemmung einer nukleinsäureamplifikation mithilfe von licht und hochempfindliches verfahren für selektive nukleinsäureamplifikation | |
| EP3152324B1 (de) | Dna-amplifizierung auf stranginvasionsbasis | |
| KR101600039B1 (ko) | 염기 특이 반응성 프라이머를 이용한 핵산 증폭방법 | |
| CN110241175B (zh) | 一种Tet2序列偏好性的研究方法 | |
| CN114134208B (zh) | 荧光定量pcr试剂盒、反应系统及核酸定量检测方法 | |
| CN114717298A (zh) | 一种多重扩增方法 | |
| CN114182001B (zh) | 非对称环介导恒温条件下合成核酸的方法及试剂盒和应用 | |
| EP3971302A1 (de) | Verfahren zum nachweis von 5-hydroxymethyliertem cytosin | |
| JP7127023B2 (ja) | 核酸検出方法、核酸検出用プライマー及び核酸検出用キット | |
| CA3183054A1 (en) | Detection of methylation status | |
| CN116769887A (zh) | 一种用于核酸扩增的捕获核苷酸及其应用 | |
| CN115725718A (zh) | 一种检测靶核酸的方法和试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20220708 Assignee: Mingde Henan Biotechnology Co.,Ltd. Assignor: Shanghai Huizhong Tongkang Biotechnology Co.,Ltd. Contract record no.: X2023980041926 Denomination of invention: A Multiple Amplification Method License type: Common License Record date: 20230918 |
|
| EE01 | Entry into force of recordation of patent licensing contract |